Veridix AI, an artificial intelligence-enbaled segment of Emmes Group, has launched its novel protocol digitisation capabilities.
The new process will aim to expedite the planning and building of clinical trials by up to 30%.
Advantage eClinical Cloud, which exists within the unified eClinical platform, uses natural language process (NLP) techniques in tandem with AI to digitalise the clinical trial protocol planning process.
It helps clinicians structure data elements such as cohorts, visit schedules and eCRFs, and is trained from previous clinical trial data.
According to Verdix AI, the technology can provide predicted eCRFS with an accuracy of more than 82%.
The update will also allow for associated edit checks based on AI predictions, helping to maintain database accuracy.
“Protocol digitisation has the potential to reshape how protocol information is used throughout the clinical research process and ecosystem. Powered by NLP and AI technologies, we can automate a significant portion of the clinical trial process.” Said CEO of Verdix, Rama Kondru.
"This unique capability allows us to accelerate the study build process and allows our data managers to focus on value added work rather than manual, tedious processes,” said Sastry Chilukuri, CEO of Emmes Group. "We’re already deploying this capability across more than 40 new study builds in both our government and commercial portfolio.”
